We are excited to share that AP Biosciences' lead candidate, AP402, was recently featured in WhatNext, a trusted U.S.-based platform focused on cancer patient education and clinical trial awareness.
The article highlights the initiation of our Phase 1/2 clinical trial of AP402, a bispecific antibody designed to target p95HER2, a treatment-resistant variant of HER2 found in up to 30% of HER2-positive tumors. AP402 aims to selectively activate immune responses in the tumor microenvironment by engaging CD137, offering a promising strategy for patients with limited options.
WhatNext is a well-established digital community that supports patients and caregivers by providing reliable, up-to-date information on emerging treatments, research breakthroughs, and real-world patient experiences.
🔗 Read the full article:
The First Patient Has Been Dosed in a Phase ½ Clinical Trial Evaluating a Therapy to Target Treatment-Resistant Variant of HER2 – WhatNext
